Loading...
Immune dysregulation as a driver of idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) affects hundreds of thousands of people worldwide, reducing their quality of life and leading to death from respiratory failure within years of diagnosis. Treatment options remain limited, with only two FDA-approved drugs available in the United States, neither of...
Saved in:
| Published in: | J Clin Invest |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
American Society for Clinical Investigation
2021
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7810481/ https://ncbi.nlm.nih.gov/pubmed/33463535 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI143226 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|